Phase II study of a combined Paclitaxel, Gemcitabine, and Cisplatin chemotherapy regimen for advanced urothelial carcinoma
Phase 2
- Conditions
- advanced urothelial carcinoma
- Registration Number
- JPRN-UMIN000001979
- Lead Sponsor
- Cancer Institute Hospital, Japanese Foundation for Cancer Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
no other active malignancy Acute myocardial infarction within 3 months of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method 1) safety 2)progression-free survival